News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sucampo Pharma Europe Presents Long-Term Safety and Efficacy Data of Lubiprostone in Chronic Idiopathic Constipation


10/21/2008 9:16:20 AM

BETHESDA, MD & OXFORD, UK--(BUSINESS WIRE)--Sucampo Pharma Europe, Ltd., a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), today announced the results from three open-labeled, long-term (6 and 12 months) clinical trials of lubiprostone (AMITIZA®). These trials were conducted between November 2001 and January 2005 and the results were previously reported in the United States. These data demonstrate that lubiprostone provided significant improvements in subjective assessments of symptoms and was well tolerated in patients with Chronic Idiopathic Constipation (CIC). Statistically significant improvements in subjective assessments were seen in secondary endpoints including constipation severity, abdominal bloating and abdominal discomfort.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES